Assessment of Efficacy and Safety of Durvalumab Plus BCG Compared to the Standard Therapy With BCG in Non-muscle Invasive Bladder Cancer
Clinical trial NCT03528694 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT03528694
- Sponsor
- AstraZeneca
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2018-05-14
- Primary completion
- 2025-04-03
- Enrollment
- 1018
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.